Presented by Sanjay Joshi
Chief Technical Officer (CTO), Life Sciences. EMC Isilon Storage Division
With respect to disease, we humans are the manifestation of our rare variants.
As the "clinical effect chasm" engulfs the efforts to understand the "N of 1" trials moving forward, there is a growing need for the re-evaluation of sample sizes in whole genome sequencing and related methods like RNA-seq, ChIP-seq and their upstream validation.
We will present an overview of the requirements to move Galaxy into the Clinical realm.